[1] Ghib Para CG, Sferdian MF, Daȿcǎu V, et al. Clinical and morphological considerations in one case with cervical cancer and right ureterohydronephrosis[J]. Rom J Morphol Embryol, 2016, 57(3):1155-1158.
[2] Baker S, Dahele M, Lagerwaard FJ, et al. A critical review of recent developments in radiotherapy for non-small cell lung cancer[J]. Radiat Onco, 2016, 11(1):115. DOI:10.1186/s13014-016-0693-8.
[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[4] Larson H. The world must accept that the HPV vaccine is safe[J]. Nature, 2015, 528(7580):9. DOI:10.1038/528009a.
[5] Adey A, Burton JN, Kitzman JO, et al. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line[J]. Nature, 2013, 500(7461):207-211. DOI:10.1038/nature12064.
[6] Wardak S. Human Papillomavirus (HPV) and cervical cancer[J]. Med Dosw Mikrobiol, 2016, 68(1):73-84.
[7] da Silva RM, Pinezi JC, Macedo LE, et al. Current situation of high-dose-rate brachytherapy for cervical cancer in Brazil[J]. Radiol Bras, 2014, 47(3):159-164. DOI:10.1590/0100-3984.2013.1859.
[8] Vargo JA, Beriwal S. Image-based brachytherapy for cervical cancer[J]. World J Clin Oncol, 2014, 5(5):921-930. DOI:10.5306/wjco.v5.i5.921.
[9] Melegari M, Scaglioni PP, Wands JR. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication[J]. J Virol, 1998, 72(3):1737-1743.
[10] Zhao Y, Li H, Zhang Y, et al. Oncoprotein HBXIP modulates abnormal lipid metabolism and growth of breast cancer cells by activating the LXRs/SREBP-1c/FAS signaling cascade[J]. Cancer Res, 2016, 76(16):4696-4707. DOI:10.1158/0008-5472.CAN-15-1734.
[11] Li L, Fang R, Liu B, et al. Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth[J]. Oncogene, 2016, 35(31):4048-4057. DOI:10.1038/onc.2015.476.
[12] Wang Y, Fang R, Cui M, et al. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer[J]. Cancer Lett, 2017, 385:234-242. DOI:10. 1016/j.canlet.2016.10.018.
[13] Li N, Wang Y, Che S, et al. HBXIP over expression as an Independent biomarker for cervical cancer[J]. Exp Mol Pathol, 2017, 102(1):133-137. DOI:10.1016/j.yexmp.2017.01.009.
[14] Li Y, Wang Z, Shi H, et al. HBXIP and LSD1 scaffolded by lncRNA hotair mediate transcriptional activation by c-Myc[J]. Cancer Res, 2016, 76(2):293-304. DOI:10.1158/0008-5472.CAN-14-3607.
[15] Li H, Liu Q, Wang Z, et al. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer[J]. J Biol Chem, 2015, 290(37):22649-22661. DOI:10.1074/jbc.M115.658468.
[16] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30. DOI:10.3322/caac.21332.
[17] Torre LA, Sauer AM, Chen MS, et al.Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016:Converging incidence in males and females[J]. CA Cancer J Clin, 2016, 66(3):182-202. DOI:10.3322/caac.21335.
[18] Desantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016:Progress and opportunities in reducing racial disparities[J]. CA Cancer J Clin, 2016, 66(4):290-308. DOI:10.3322/caac.21340.
[19] Fu ZC, Wang FM, Cai JM. Gene expression changes in residual advanced cervical cancer after radiotherapy:indicators of poor prognosis and radioresistance[J]. Med Sci Monit, 2015, 21:1276-1287. DOI:10.12659/MSM.893689.
[20] Zhao Y, Moran MS, Yang Q, et al. Metadherin regulates radioresistance in cervical cancer cells[J]. Oncol Rep, 2012, 27(5):1520-1526. DOI:10.3892/or.2012.1692.
[21] Garcia-Saez I, Lacroix FB, Blot D, et al. Structural characterization of HBXIP:the protein that interacts with the anti-apoptotic protein survivin and the oncogenic viral protein HBx[J]. J Mol Biol, 2011, 405(2):331-340. DOI:10.1016/j.jmb.2010.10.046.
[22] Du G, Cao D, Meng L. miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells[J]. Mol Med Rep, 2017, 15(5):2713-2719. DOI:10.3892/mmr.2017.6340.
[23] Zhang E, Shi H, Yang L, et al. Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth[J]. Oncol Rep, 2017, 38(1):359-367. DOI:10.3892/or.2017.5652.
[24] Wu J, Hu G, Dong Y, et al. Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells[J]. J Cell Mol Med, 2017, 21(6):1171-1181. DOI:10.1111/jcmm.13049.
[25] Tan Y, Huang N, Zhang X, et al. KIAA0247 suppresses the prolif-eration, angiogenesis and promote apoptosis of human glioma through inactivation of the AKT and Stat3 signaling pathway[J]. Oncotarget, 2016, 7(52):87100-87113. DOI:10.18632/oncotarget.13527.
[26] Song L, Liu S, Zhang L, et al. MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway[J]. Tumour Biol, 2016, 37(9):12161-12168. DOI:10.1007/s13277-016-5073-3.
[27] Shimura T. Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy[J]. Int J Radiat Biol, 2017, 93(4):381-385. DOI:10.1080/09553002.2016.1257832.
[28] Liu S, Li L, Zhang Y, et al. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells[J]. J Biol Chem, 2012, 287(36):30228-30239. DOI:10.1074/jbc.M112.343947.